Research ExplorerPublicationsThe mineralocorticoid receptor agonist, fludrocortisone, inh...

The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.

Standard

The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. / Otte, Christian; Jahn, Holger; Yassouridis, Alexander; Arlt, Josef; Stober, Nina; Maass, Philip; Wiedemann, Klaus; Kellner, Michael.

In: LIFE SCI, Vol. 73, No. 14, 14, 2003, p. 1835-1845.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Otte, C, Jahn, H, Yassouridis, A, Arlt, J, Stober, N, Maass, P, Wiedemann, K & Kellner, M 2003, 'The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.', LIFE SCI, vol. 73, no. 14, 14, pp. 1835-1845. <http://www.ncbi.nlm.nih.gov/pubmed/12888122?dopt=Citation>

APA

Otte, C., Jahn, H., Yassouridis, A., Arlt, J., Stober, N., Maass, P., Wiedemann, K., & Kellner, M. (2003). The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. LIFE SCI, 73(14), 1835-1845. [14]. http://www.ncbi.nlm.nih.gov/pubmed/12888122?dopt=Citation

Vancouver

Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P et al. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. LIFE SCI. 2003;73(14):1835-1845. 14.

Bibtex

@article{9ba0ab2c5a244cf7ac2d2e17a851941e,
title = "The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.",
abstract = "Whereas animal studies have shown a clear inhibitory effect of hippocampal mineralocorticoid receptors (MR) on hypothalamic-pituitary-adrenal (HPA) axis activity, investigations in humans revealed equivocal results. To further clarify the influence of MR in HPA activity we studied 10 healthy men during the circadian nadir of HPA activity (14:00 to 21:00) after pre-treatment with 3 g metyrapone to minimize the impact of basal endogenous cortisol secretion. On three separate occasions, in a placebo-controlled design, subjects received in a randomized order either 0.5 mg fludrocortisone p.o. or 0.2 mg aldosterone i.v. or placebo. Fludrocortisone exerted a significant inhibition of ACTH, cortisol and 11-desoxycortisol (p <0.05), whereas no such effect was observed after aldosterone or placebo. These preliminary data suggest that MR are involved in the inhibition of the HPA axis during the circadian nadir of glucocorticoid concentrations in humans.",
author = "Christian Otte and Holger Jahn and Alexander Yassouridis and Josef Arlt and Nina Stober and Philip Maass and Klaus Wiedemann and Michael Kellner",
year = "2003",
language = "Deutsch",
volume = "73",
pages = "1835--1845",
journal = "LIFE SCI",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "14",

}

RIS

TY - JOUR

T1 - The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone.

AU - Otte, Christian

AU - Jahn, Holger

AU - Yassouridis, Alexander

AU - Arlt, Josef

AU - Stober, Nina

AU - Maass, Philip

AU - Wiedemann, Klaus

AU - Kellner, Michael

PY - 2003

Y1 - 2003

N2 - Whereas animal studies have shown a clear inhibitory effect of hippocampal mineralocorticoid receptors (MR) on hypothalamic-pituitary-adrenal (HPA) axis activity, investigations in humans revealed equivocal results. To further clarify the influence of MR in HPA activity we studied 10 healthy men during the circadian nadir of HPA activity (14:00 to 21:00) after pre-treatment with 3 g metyrapone to minimize the impact of basal endogenous cortisol secretion. On three separate occasions, in a placebo-controlled design, subjects received in a randomized order either 0.5 mg fludrocortisone p.o. or 0.2 mg aldosterone i.v. or placebo. Fludrocortisone exerted a significant inhibition of ACTH, cortisol and 11-desoxycortisol (p <0.05), whereas no such effect was observed after aldosterone or placebo. These preliminary data suggest that MR are involved in the inhibition of the HPA axis during the circadian nadir of glucocorticoid concentrations in humans.

AB - Whereas animal studies have shown a clear inhibitory effect of hippocampal mineralocorticoid receptors (MR) on hypothalamic-pituitary-adrenal (HPA) axis activity, investigations in humans revealed equivocal results. To further clarify the influence of MR in HPA activity we studied 10 healthy men during the circadian nadir of HPA activity (14:00 to 21:00) after pre-treatment with 3 g metyrapone to minimize the impact of basal endogenous cortisol secretion. On three separate occasions, in a placebo-controlled design, subjects received in a randomized order either 0.5 mg fludrocortisone p.o. or 0.2 mg aldosterone i.v. or placebo. Fludrocortisone exerted a significant inhibition of ACTH, cortisol and 11-desoxycortisol (p <0.05), whereas no such effect was observed after aldosterone or placebo. These preliminary data suggest that MR are involved in the inhibition of the HPA axis during the circadian nadir of glucocorticoid concentrations in humans.

M3 - SCORING: Zeitschriftenaufsatz

VL - 73

SP - 1835

EP - 1845

JO - LIFE SCI

JF - LIFE SCI

SN - 0024-3205

IS - 14

M1 - 14

ER -